Related Experiment Video
Updated: Mar 9, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Nanomedicine as a strategy to fight thrombotic diseases
Mariana Varna1, Maya Juenet1, Richard Bayles2
1Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Institut Galilée, Université Paris 13, Sorbonne Paris Cité, 93430, Villetaneuse, France; Inserm, U1148, Cardiovascular Bio-Engineering, X. Bichat Hospital, 75018, Paris, France; Institut Galilée, Université Paris 13, Sorbonne Paris Cité, 93430, Villetaneuse, France.
Abstract:
This review highlights the preclinical and clinical research based on the use of nano- and micro-carriers in thrombolytic drug delivery. Ischemic heart and stroke caused by thrombosis are the main causes of death in the world. Because of their inactivation in the blood, high doses of thrombolytics are administered to patients, increasing the risk of intracranial hemorrhage. Preclinical research conducted with lipid, polymer or magnetic nanoparticles loaded with thrombolytic drugs showed an enhancement of thrombolysis and a reduction of undesirable side effects. Targeted nanocarriers exhibited an increased accumulation into clot. Clinical trials were already conducted with lipid-based microbubbles combined with ultrasound and thrombolytic drug and showed thrombolysis improvement. Future validation of nanosystems is awaited in clinic. This research opens new strategies for the management of thrombotic diseases.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clot Retraction and Fibrinolysis

